- No major US guideline tells every man to get a PSA test. They disagree on when to start the conversation: 40, 45, 50 or 55, depending on the guideline and your risk
- The benefit is real but modest. In the European ERSPC trial, screening cut prostate cancer deaths by 13% over 23 years: one death prevented per 456 men invited
- The main harm is overdiagnosis: finding slow cancers that would never have caused harm, in an estimated 20% to 50% of screen-detected cases, says the USPSTF
- Black men, men with a father or brother diagnosed young, and BRCA2 carriers are at higher risk and may start earlier
- Screening is gentler than it was. MRI can now come before biopsy, and in one US registry, monitoring instead of treating low-risk cancer rose from 26.5% in 2014 to 59.6% in 2021
Our guide to blood tests after 40 promised PSA its own article. It's the routine-looking blood test where experts genuinely disagree, and the right answer depends on your age, your family and how you weigh the trade-offs.
Here's what the big trials found, what each guideline says for your age, and what to ask. It's an evidence summary, not medical advice: make the decision with your own doctor.
What PSA Is, and Why It's Contested
Prostate-specific antigen (PSA) is a protein made by both normal and cancerous prostate cells, measured in a blood test. Generally a level above 4.0 ng/mL is considered abnormal, though some doctors use higher cut-offs for older men and lower ones for younger men (National Cancer Institute).
But PSA isn't specific to cancer. An enlarged prostate and inflammation raise it too, and only about 25% of men who have a biopsy because of a raised PSA are found to have prostate cancer (NCI). The US Preventive Services Task Force (USPSTF) lists the trade-offs plainly (USPSTF, 2018):
- The benefit: screening men aged 55 to 69 may prevent about 1.3 prostate cancer deaths over about 13 years, and about 3 cases of cancer that has spread, per 1,000 men screened.
- False alarms: "frequent false-positive results and psychological harms".
- Biopsy harms: about 1% of prostate biopsies lead to complications needing a hospital stay.
- Overdiagnosis: 20% to 50% of men diagnosed through screening may be overdiagnosed, with a cancer that would never have caused harm.
- Treatment harms: after prostate removal, about 1 in 5 men have long-term urinary incontinence needing pads and 2 in 3 have long-term erectile dysfunction; after radiotherapy, more than half have long-term erectile dysfunction.
That's the debate in miniature: a few men avoid dying of prostate cancer, while more are diagnosed with, and sometimes treated for, cancers that were never going to hurt them.
What the Big Trials Found
Evidence: Strong — three large randomised trials, mixed resultsERSPC: a lasting benefit in Europe
The European Randomized Study of Screening for Prostate Cancer (ERSPC) randomly assigned 162,236 men aged 55 to 69 in eight countries between 1993 and 2003. 72,888 were offered PSA screening, typically every 4 years; 89,348 weren't invited. The 23-year results appeared in the New England Journal of Medicine in October 2025 (Roobol, NEJM 2025; ASCO Post).
- Deaths: 13% fewer prostate cancer deaths in the screening group (rate ratio 0.87; 95% CI 0.80 to 0.95). The absolute reduction was 0.22%, about 2 deaths per 1,000 men invited.
- The trade: one death prevented per 456 men invited and per 12 men diagnosed, better than the 628 and 18 at 16 years.
- Extra diagnoses: 14% of the screening group were diagnosed with prostate cancer, against 12% of controls.
- False alarms: 28% of screened men had at least one positive result, but only 24% of the biopsies that followed confirmed cancer.
The authors concluded that future screening "should adopt risk-based approaches to minimize overdiagnosis while maintaining clinical benefits." Anssi Auvinen of Tampere University, one of the principal investigators, added: "the effect starts to wane once screening is discontinued and largely disappears within nine years" (Tampere University).
The cost of preventing one death has fallen with time
Roobol et al., NEJM 2025 (abstract). "Diagnosed" counts men diagnosed with prostate cancer for each death prevented.
PLCO: no difference, but a contaminated comparison
The US PLCO (Prostate, Lung, Colorectal and Ovarian) trial randomised 76,683 men aged 55 to 74 between 1993 and 2001. The screening group got yearly PSA tests for 6 years and rectal exams for 4. After a median of about 15 years, there were 255 prostate cancer deaths in the screening group and 244 in the control group (rate ratio 1.04; 95% CI 0.87 to 1.24), so no reduction (Pinsky, Cancer 2017).
The catch: an estimated 86% of control-group men had a PSA test anyway, against 99% in the screening group. The authors wrote that the result "can be viewed as showing no benefit of organized screening versus opportunistic screening" (Pinsky, Cancer 2017), which is not the same as showing PSA testing doesn't work.
CAP: one test, a small effect
The UK CAP trial asked what a single PSA test does. It included 415,357 men aged 50 to 69 registered with GP practices in England and Wales. Practices were randomised, and men in the intervention group got one invitation for a PSA test, with a biopsy offered if PSA was 3.0 ng/mL or more. Only 40% of invited men had a test (Martin, JAMA 2024).
After a median of 15 years, 0.69% of the invited group had died of prostate cancer against 0.78% of the control group (rate ratio 0.92; 95% CI 0.85 to 0.99), a difference of 0.09 percentage points. More low-grade cancers were found (Gleason 6 or lower: 2.2% vs 1.6%), and deaths from all causes didn't differ. The authors called the absolute reduction in deaths "small", and the University of Bristol estimated that one in six cancers found by the single test were overdiagnosed (University of Bristol).
What each trial tested, and what it found
| Trial | Who and what | Prostate cancer deaths | The catch |
|---|---|---|---|
| ERSPC 8 European countries | 162,236 men aged 55–69; PSA usually every 4 years | 13% lower at 23 years RR 0.87 (0.80–0.95); 1 death prevented per 456 invited | 12 men diagnosed per death prevented; benefit wanes after screening stops |
| PLCO United States | 76,683 men aged 55–74; yearly PSA for 6 years | No difference at about 15 years RR 1.04 (0.87–1.24) | 86% of the control group had a PSA test anyway |
| CAP England and Wales | 415,357 men aged 50–69; one PSA test invitation | 0.69% vs 0.78% at 15 years RR 0.92 (0.85–0.99) | Only 40% of invited men were tested; more low-grade cancers found |
Roobol, NEJM 2025; Pinsky, Cancer 2017; Martin, JAMA 2024. RR = rate ratio (95% confidence interval).
The Guidelines, Age by Age
Together, the trials say screening can cut prostate cancer deaths by a small absolute amount, at the cost of extra diagnoses. Guideline bodies weigh that differently.
USPSTF (2018): an individual decision from 55 to 69
For men aged 55 to 69, the USPSTF says the decision to have periodic PSA screening "should be an individual one" (grade C). It recommends against PSA screening in men 70 and older (grade D). It made no separate recommendation for Black men or men with a family history, though it named both as major risk factors, alongside age (USPSTF).
The Task Force's page says the topic "is being updated". It posted a final research plan on 21 December 2023 (USPSTF), but as of mid-October 2026 we found no new draft recommendation on its site. The 2018 statement still stands.
American Cancer Society: talk about it at 50, 45 or 40
The ACS recommends that men "have a chance to make an informed decision with their health care provider" about screening, starting (ACS, revised November 2023):
- At 50 for men at average risk who are expected to live at least 10 more years.
- At 45 for men at high risk, which includes African American men and men whose father or brother was diagnosed before 65.
- At 40 for men at even higher risk: more than one first-degree relative diagnosed at an early age.
With a PSA below 2.5 ng/mL, retesting every 2 years may be enough; at 2.5 or higher, yearly. Men without symptoms and with less than a 10-year life expectancy shouldn't be offered screening.
AUA/SUO (2023): a baseline PSA in your late 40s
The urologists' guideline (American Urological Association and Society of Urologic Oncology) is the most proactive (AUA/SUO, 2023):
- Clinicians "may begin prostate cancer screening and offer a baseline PSA test to people between ages 45 to 50 years."
- They "should offer regular prostate cancer screening every 2 to 4 years to people aged 50 to 69 years", after shared decision-making.
- They should offer screening from 40 to 45 for people at higher risk because of Black ancestry, inherited gene changes (germline mutations) or a strong family history.
- The interval can be personalised, or screening stopped, based on age, PSA, risk, health and preference.
The UK: targeted screening for BRCA2 carriers
The UK has no screening programme for all men, but men can ask their GP for a PSA test after discussing the pros and cons. In May 2026 the UK National Screening Committee recommended a PSA test every two years for men aged 45 to 61 with a confirmed BRCA2 gene change and a relevant family history. It advised against screening all men, Black men, or men with a family history but no BRCA2 change. As Cancer Research UK puts it, "the PSA blood test is not a reliable enough test to screen all men." The UK government accepted the recommendation for England in June 2026, with screening expected to roll out in 2027; Scotland, Wales and Northern Ireland are still considering it (DHSC; UK NSC; Cancer Research UK).
What each guideline says at your age
| Age | USPSTF (2018) | American Cancer Society | AUA/SUO (2023) | UK |
|---|---|---|---|---|
| 40–44 | Not covered | Discuss at 40 if more than one close relative diagnosed early | Offer screening from 40–45 if higher risk | No national screening; can ask GP |
| 45–49 | Not covered | Discuss at 45 if Black, or father/brother diagnosed before 65 | May offer a baseline PSA (45–50) | From 2027 (England): PSA every 2 years, ages 45–61, for BRCA2 carriers with a family history otherwise no national screening; can ask GP |
| 50–54 | Not covered | Discuss at 50 if average risk and expected to live 10+ years | Offer screening every 2–4 years | BRCA2 programme continues to 61 otherwise no national screening; can ask GP |
| 55–69 | Individual decision grade C | If screening: retest every 2 years if PSA under 2.5; yearly if 2.5+ | Offer screening every 2–4 years to age 69 | BRCA2 programme to 61 otherwise no national screening; can ask GP |
| 70+ | Recommends against grade D | Not offered if life expectancy under 10 years | Personalise or stop, by age, PSA and health | No national screening; can ask GP |
USPSTF 2018; ACS (revised November 2023); AUA/SUO Early Detection of Prostate Cancer guideline, 2023; UK National Screening Committee (May 2026); Department of Health and Social Care (June 2026).
Who Should Start the Conversation Earlier
About 1 in 8 US men will be diagnosed with prostate cancer during their lifetime, and about 1 in 49 will die of it. The ACS estimates 333,830 new US cases and 36,320 deaths in 2026; the average age at diagnosis is about 68 (ACS). Three groups carry more risk:
- Black men. Compared with White men, incidence is 67% higher and the death rate twice as high, according to the ACS's 2025 prostate cancer statistics report (ACS, 2025).
- Family history. Having a father or brother with prostate cancer "more than doubles a man's risk" (ACS). The USPSTF says men whose father or brother had advanced or metastatic prostate cancer, or died of it, are probably the most likely to benefit from screening.
- BRCA2 (and BRCA1) carriers. The National Cancer Institute says 19% to 61% of men with a harmful BRCA2 change, and 7% to 26% with a BRCA1 change, will get prostate cancer by 80, against about 10.6% of men in general (NCI). If cancer runs in your family, ask your doctor whether genetic counselling makes sense.
Why a Raised PSA Is Less Fraught Than It Was
Much of the case against screening came from what followed a raised PSA: biopsies, and treatment for cancers that might never have caused harm. Two changes have softened that.
MRI before biopsy. The AUA/SUO guideline says clinicians may use MRI before a first biopsy to better detect clinically significant cancers, and should get one before a repeat biopsy if there hasn't been one (AUA/SUO). A suspicious area on MRI can then be biopsied directly (NCI).
Active surveillance. This means monitoring a low-risk cancer instead of treating it straight away; the USPSTF describes it as an approach that "seeks to limit the harms of treatment". In the AUA's AQUA registry of 20,809 men with low-risk disease at 349 US practices, its use rose from 26.5% in 2014 to 59.6% in 2021 (Cooperberg, JAMA Netw Open 2023, via The ASCO Post).
Before and After the Test
Things that can raise PSA temporarily
According to the National Cancer Institute (NCI):
- Ejaculation and vigorous exercise, such as cycling, can raise PSA for a short time.
- An enlarged prostate (BPH) or prostatitis (inflammation of the prostate) can raise it.
- A recent prostate biopsy can raise it for a month or two.
- Finasteride and dutasteride lower PSA, so tell your doctor if you take either.
Ask your doctor or lab whether you should avoid sex or a long ride in the days before the test.
What a "high" result usually means next
A single raised PSA isn't a diagnosis. The NCI says a doctor may repeat the test in 6 to 8 weeks, and the AUA/SUO guideline says to repeat a newly raised PSA before imaging or biopsy. If it stays high, options include more PSA tests, a rectal exam, an MRI and, if needed, a biopsy.
Questions to ask your doctor
- Given my age, ethnicity and family history, which guideline fits me, and when should we start talking about it?
- Should I get a baseline PSA now, and how often should I be retested if it's low?
- What would we do first if my PSA came back raised?
- Would I have an MRI before any biopsy?
- If a low-risk cancer were found, would active surveillance be an option?
Frequently Asked Questions
A real benefit, a real trade-off, and your call.
PSA screening prevents a small number of prostate cancer deaths, and the benefit in the longest trial has grown with time. The price is extra diagnoses, though MRI and active surveillance now soften what follows a raised result.
In your 40s, learn your family history and ask your doctor when to start, especially if you're Black, carry a BRCA2 change or had a father or brother diagnosed young. From 55 to 69, all three US guidelines support an informed choice. Past 70, the case weakens. Decide with your doctor, not by default.
Sources
- Roobol MJ, de Vos II, Månsson M, et al. European Study of Prostate Cancer Screening — 23-Year Follow-up. New England Journal of Medicine 2025;393(17):1669–1680 (doi:10.1056/NEJMoa2503223). As reported by The ASCO Post (November 2025).
- Tampere University. Study confirms sustained reduction in prostate cancer mortality with PSA screening. 3 November 2025.
- Pinsky PF, Prorok PC, Yu K, et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer 2017;123(4):592–599 (doi:10.1002/cncr.30474).
- Martin RM, Turner EL, Young GJ, et al. Prostate-specific antigen screening and 15-year prostate cancer mortality: a secondary analysis of the CAP randomized clinical trial. JAMA 2024;331(17):1460, published online 6 April 2024 (doi:10.1001/jama.2024.4011).
- University of Bristol. Screening with a PSA test has a small impact on prostate cancer deaths but leads to overdiagnosis. April 2024.
- US Preventive Services Task Force. Prostate Cancer: Screening. Final recommendation, 8 May 2018 (update in progress).
- US Preventive Services Task Force. Final Research Plan: Screening for Prostate Cancer. 21 December 2023.
- American Cancer Society. American Cancer Society Recommendations for Prostate Cancer Early Detection. Revised 22 November 2023.
- American Cancer Society. Key Statistics for Prostate Cancer (2026 estimates) and Prostate Cancer Risk Factors.
- American Cancer Society. New ACS prostate cancer statistics report. 2 September 2025 (report in CA: A Cancer Journal for Clinicians).
- American Urological Association and Society of Urologic Oncology. Early Detection of Prostate Cancer: AUA/SUO Guideline (2023). Part I: prostate cancer screening. Wei JT, Barocas D, Carlsson S, et al. Journal of Urology 2023;210(1):46–53 (doi:10.1097/JU.0000000000003491).
- National Cancer Institute. Prostate-Specific Antigen (PSA) Test.
- National Cancer Institute. BRCA Gene Changes: Cancer Risk and Genetic Testing.
- Cooperberg MR, Meeks W, Fang R, et al. Time trends and variation in the use of active surveillance for management of low-risk prostate cancer in the US. JAMA Network Open 2023;6(3):e231439 (doi:10.1001/jamanetworkopen.2023.1439). Also reported by The ASCO Post (March 2023).
- UK National Screening Committee. UK NSC opens consultation on draft prostate cancer screening recommendation. 28 November 2025.
- UK National Screening Committee. Minutes published of UK NSC March 2026 meeting. 28 May 2026.
- Department of Health and Social Care. Major expansion of research and treatment for prostate cancer. 2 June 2026.
- Cancer Research UK. UK NSC recommends targeted prostate cancer screening. 28 May 2026; and Screening for prostate cancer.